|
Maternal Serum Alpha-Fetoprotein (MSAFP) Testing:
NTDs are associated with a high rate of perinatal mortality, morbidity, and long-term physical and developmental disability. NTDs include the fatal condition anencephaly, various forms of spina bifida such as the severely debilitating condition lumbar meningomyelocele, and potentially surgically correctable lesions such an encephalocele. A family history of NTD in either parent or in one or more siblings results in an increased risk of an NTD in an infant. However, 90 to 95 % of all NTDs occur in families without a family history. Only about 30% of pregnant women receive the recommended daily amount of folic acid known to significantly reduce NTDs. Maternal serum alpha-fetoprotein (MSAFP) testing represents the most significant advance in the early detection of NTDs and other serious fetal malformations. MSAFP levels are elevated in the presence of an open NTD 980 to 90% of all cases). Elevated MSAFP levels also occur with omphalocele, gastroschisis, congenital nephrosis, Turner syndrome with cystic hygroma, fetal bowel obstruction, and teratoma. Fetal growth retardation, fetal death, and other adverse outcomes are also associated with abnormally high levels of MSAFP. MSAFP testing for all pregnancies became an expected standard of care in the United States in the mid-1980’s. The American College of Obstetricians and Gynecologists issued a Professional Liability Alert to all obstetricians regarding the duty to advise every prenatal patient of the availability of this test. Statements recommending MSAFP testing for all pregnancies have also been issued by the American Academy of Pediatrics and the American Society of Human Genetics. MSAFP screening has been shown to be cost-beneficial in terms of early recognition of NTDs In pregnancies with NTDs, delivery by cesarean section before the onset of labor results in better motor function than vaginal delivery or delivery by cesarean section after a period of labor. |